GLP-1 Therapies Outperform Bariatric Surgery in Cancer Risk Reduction A 2025 study published in eClinicalMedicine (Wolff Sagy Y et al.) compared cancer outcomes in patients receiving GLP-1 receptor agonists versus those who had undergone bariatric metabolic surgery
A randomized, controlled trial of liraglutide for adolescents with obesity
Can Eli Lilly produce enough retatrutide to meet what will likely be enormous demand
This is why fatigue on semaglutide and GLP-1 fatigue are so common
Licensed options in the UK include orlistat (oral), semaglutide 2.4 mg (Wegovy, approved by NICE TA875 for eligible patients), and tirzepatide (Mounjaro for type 2 diabetes
Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint